Company intends to advance felzartamab into late-stage development in Primary Membranous Nephropathy and other autoantibody-driven immune-mediated diseases Primary Membranous Nephropathy is a rare, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback